blue cross blue shield cover glp-1 Results of two-year study show limited adherence, savings for obesity drugs glp 1 covered by blue

The Institute for Safe Medication Practices Canada issued a bulletin last week after a patient who had been taking weekly semaglutide injections for weight loss vomited a large volume of undigested food while waking from anesthesia following orthopedic surgery

'fb_in_app_browser_popup } 'in_app_browser_popup } 'product } per order

In 17,604 adults with cardiovascular disease and obesity but without diabetes, semaglutide produced a 20 percent relative risk reduction in major adverse cardiovascular events

The medication mimics the hormone GLP-1, which regulates appetite and food intake which can help lead to reduced hunger and subsequently, calorie consumption